Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03241810
Title Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.